EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSPCOG00000013718
Gene Symbol: PPP3CA
4 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Kinase 2

Ensembl ID : ENSPCOG00000025086
Gene Symbol: PTK2
4 Cross references
326 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSPCOG00000026528
Gene Symbol: PTK2B
4 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPCOG00000027416
Gene Symbol: PTPN11
4 Cross references
251 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPCOG00000028533
Gene Symbol: PTPRB
4 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purine Nucleoside Phosphorylase

Ensembl ID : ENSPCOG00000023019
Gene Symbol: PNP
4 Cross references
429 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2x 3

Ensembl ID : ENSPCOG00000025770
Gene Symbol: P2RX3
4 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2x 7

Ensembl ID : ENSPCOG00000027651
Gene Symbol: P2RX7
4 Cross references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y1

Ensembl ID : ENSPCOG00000026439
Gene Symbol: P2RY1
4 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y12

Ensembl ID : ENSPCOG00000011471
Gene Symbol: P2RY12
4 Cross references
180 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor Activity Modifying Protein 1

Ensembl ID : ENSPCOG00000004479
Gene Symbol: RAMP1
4 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSPCOG00000024336
Gene Symbol: RIPK1
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).